Hyperprogressive Disease After Treatment With Checkpoint Inhibitors

Immunotherapy, immune checkpoint inhibitors (ICIs) in particular, has dramatically changed the treatment and outcome of patients with many forms of cancer, including non–small cell lung cancer (NSCLC). The mechanism of action of these agents is to exert an antitumor immunity through T cells that…

Read the full article here

Related Articles